Progenics Pharmaceuticals (NASDAQ:PGNX) will post its quarterly earnings results before the market opens on Wednesday, March 7th. Analysts expect Progenics Pharmaceuticals to post earnings of ($0.23) per share for the quarter.
Progenics Pharmaceuticals (PGNX) opened at $6.71 on Wednesday. The company has a market capitalization of $471.51, a PE ratio of -8.49 and a beta of 3.40. Progenics Pharmaceuticals has a 1-year low of $4.60 and a 1-year high of $11.72. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.80.
Several analysts have issued reports on PGNX shares. Cantor Fitzgerald restated a “buy” rating and set a $15.00 price objective on shares of Progenics Pharmaceuticals in a research note on Wednesday, January 17th. Zacks Investment Research upgraded Progenics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a research note on Thursday, January 4th. BidaskClub upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 9th. Finally, ValuEngine upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, December 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $12.35.
TRADEMARK VIOLATION NOTICE: This article was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3226835/progenics-pharmaceuticals-pgnx-set-to-announce-quarterly-earnings-on-wednesday.html.
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.